Information
○ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025;...
Original sourceAI Summary
Cellectis expects UCART22 Phase 1 data announcement in Q3 2025. AstraZeneca invested $140 million in Cellectis, enhancing R&D efforts. Cellectis holds $264 million in cash, funding operations until mid-2027. FDA granted ODD for UCART22 and CLLS52, aiding development. Focus on advancing key trials UCART22 and UCART20x22 continues.
Sentiment Rationale
The investment from AstraZeneca and ODDs boost Cellectis' future prospects, resembling past cases like Novartis with Kymriah.
Trading Thesis
The ongoing developments and expected data readouts will gradually influence CLLS's market position over time.
Market-Moving
- Cellectis expects UCART22 Phase 1 data announcement in Q3 2025.
- AstraZeneca invested $140 million in Cellectis, enhancing R&D efforts.
- Cellectis holds $264 million in cash, funding operations until mid-2027.
Key Facts
- Cellectis expects UCART22 Phase 1 data announcement in Q3 2025.
- AstraZeneca invested $140 million in Cellectis, enhancing R&D efforts.
- Cellectis holds $264 million in cash, funding operations until mid-2027.
- FDA granted ODD for UCART22 and CLLS52, aiding development.
- Focus on advancing key trials UCART22 and UCART20x22 continues.
Companies Mentioned
- AZN (AZN)
- NOVN (NOVN)
- ALLG (ALLG)
Corporate Developments
AstraZeneca's investment and FDA designations significantly enhance the potential of Cellectis' products.